Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?

Clinical Pharmacokinetics
Vera E BukkemsDavid M Burger

Abstract

Although the separate effects of drug-drug interactions and pregnancy on antiretroviral drug pharmacokinetics have been widely studied and described, their combined effect is largely unknown. Physiological changes during pregnancy may change the extent or clinical relevance of a drug-drug interaction in a pregnant woman. This review aims to provide a detailed overview of the mechanisms, magnitude, and clinical significance of antiretroviral drug-drug interactions in pregnant women. We performed a literature search and selected studies that compared the magnitude of drug-drug interactions with antiretroviral drugs in pregnant vs non-pregnant women. Forty-eight papers examining drug-drug interactions during pregnancy were selected, of which the majority focused on pharmacokinetic boosting. Other selected studies examined the drug-drug interactions between efavirenz and lumefantrine, efavirenz and tuberculosis drugs, etravirine and tenofovir disoproxil fumarate, atazanavir and tenofovir disoproxil, and mefloquine and nevirapine in pregnant compared to non-pregnant women. The clinical significance of antiretroviral drug-drug interactions changed during pregnancy from a minimal effect to a contra-indication. In almost all cases, the...Continue Reading

References

Oct 1, 1970·The Journal of Obstetrics and Gynaecology of the British Commonwealth·E ParryA C Turnbull
Dec 10, 1997·Clinical Pharmacokinetics·R LoebsteinG Koren
Mar 19, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·L I Malaty, J J Kuper
Dec 12, 2001·Clinical Pharmacokinetics·P F SmithG D Morse
Jan 22, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·M Dawes, P J Chowienczyk
Jul 20, 2002·Clinical Pharmacokinetics·Luis F López-CortésJerónimo Pachón
Jun 24, 2003·AIDS·Bradley W KoselFrancesca T Aweeka
May 25, 2004·Antimicrobial Agents and Chemotherapy·Anne-Marie TaburetPierre-Marie Girard
May 29, 2004·European Journal of Clinical Pharmacology·J HeadleyUNKNOWN ALSPAC Study Team
Oct 22, 2004·Journal of Clinical Pharmacology·Niresh HariparsadPankaj B Desai
Jul 13, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Homayoun Khanlou, Charles Farthing
Sep 24, 2005·Clinical Pharmacokinetics·Gail D Anderson
Sep 22, 2006·AIDS·Alice M StekJennifer S Read
Oct 21, 2006·European Journal of Clinical Pharmacology·Rose McGreadyFrançois Nosten
Dec 13, 2006·Antimicrobial Agents and Chemotherapy·Jashvant D UnadkatRuth E Tuomala
Aug 1, 2007·European Journal of Clinical Pharmacology·Nils von HentigSebastian Harder
Dec 22, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H JeongJ H Fischer
Apr 29, 2008·Journal of Clinical Pharmacology·Cheri E KleinGeorge J Hanna
Nov 8, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark MirochnickUNKNOWN PACTG 1026s Study Team
Dec 11, 2008·Journal of Pharmaceutical Sciences·Abhishek Gulati, Phillip M Gerk
Jan 10, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Marc VermeirAraz Raoof
Jul 16, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Brookie M BestUNKNOWN International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s Study Team
Oct 6, 2010·Antimicrobial Agents and Chemotherapy·Jennifer J KiserRichard Brundage
Feb 2, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark MirochnickUNKNOWN IMPAACT 1026s Study Team
Nov 16, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Tim R CresseyUNKNOWN IMPAACT P1026s Team
Nov 23, 2011·Therapeutic Drug Monitoring·Maria Martinez-RebollarJosep Mallolas
Mar 28, 2012·Antimicrobial Agents and Chemotherapy·Darren M MossAndrew Owen
May 9, 2012·The Journal of Antimicrobial Chemotherapy·Javier A EstévezMarta Valle
Jun 13, 2012·The Journal of Antimicrobial Chemotherapy·Pauline Byakika-KibwikaConcepta Merry
Dec 12, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Kristine B PattersonAngela D M Kashuba
Jan 12, 2013·British Journal of Clinical Pharmacology·Tim R CresseyUNKNOWN IMPAACT P1026s team
Jan 15, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Michelle S CespedesJudith A Aberg
Feb 9, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Regis KreitchmannMark Mirochnick

❮ Previous
Next ❯

Citations

Jul 14, 2021·Journal of Clinical Pharmacy and Therapeutics·Nikki MulliganUNKNOWN IMPAACT P1026s Protocol Team

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of Clinical Psychiatry
S H Preskorn
Basic & Clinical Pharmacology & Toxicology
Teresa Juárez-CedilloPhilip D Hansten
Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
Marcus Gomes Bastos
Medicina clínica
Juan Carlos Juárez Giménez, José Bruno Montoro Ronsano
© 2021 Meta ULC. All rights reserved